Eton Pharma rises on study results for rare disease drug

Drug developer Eton Pharmaceuticals' ETON.O shares rise 6.2% to $15.51 premarket

Company says its experimental drug, ET-600, passed a bioequivalence study against an FDA-approved reference product with the same active ingredient for treatment of a rare condition called central diabetes insipidus (CDI)

A bioequivalence study compares a generic test formulation with the original reference drug

CDI is an uncommon problem in which the body can't properly balance fluid levels prompting to make large amounts of urine

Eton Pharma plans to file FDA marketing application in April 2025

As of last close, company's shares have more than tripled in the past 12 months